Acute respiratory distress syndrome in COVID-19 : possible mechanisms and therapeutic management
© 2021. The Author(s)..
COVID-19 pandemic is a serious concern in the new era. Acute respiratory distress syndrome (ARDS), and lung failure are the main lung diseases in COVID-19 patients. Even though COVID-19 vaccinations are available now, there is still an urgent need to find potential treatments to ease the effects of COVID-19 on already sick patients. Multiple experimental drugs have been approved by the FDA with unknown efficacy and possible adverse effects. Probably the increasing number of studies worldwide examining the potential COVID-19 related therapies will help to identification of effective ARDS treatment. In this review article, we first provide a summary on immunopathology of ARDS next we will give an overview of management of patients with COVID-19 requiring intensive care unit (ICU), while focusing on the current treatment strategies being evaluated in the clinical trials in COVID-19-induced ARDS patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Pneumonia (Nathan Qld.) - 13(2021), 1 vom: 06. Dez., Seite 14 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aslan, Anolin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ARDS |
|---|
| Anmerkungen: |
Date Revised 12.12.2021 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1186/s41479-021-00092-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM33409318X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33409318X | ||
| 003 | DE-627 | ||
| 005 | 20231225223004.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s41479-021-00092-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1113.xml |
| 035 | |a (DE-627)NLM33409318X | ||
| 035 | |a (NLM)34872623 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aslan, Anolin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Acute respiratory distress syndrome in COVID-19 |b possible mechanisms and therapeutic management |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 12.12.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2021. The Author(s). | ||
| 520 | |a COVID-19 pandemic is a serious concern in the new era. Acute respiratory distress syndrome (ARDS), and lung failure are the main lung diseases in COVID-19 patients. Even though COVID-19 vaccinations are available now, there is still an urgent need to find potential treatments to ease the effects of COVID-19 on already sick patients. Multiple experimental drugs have been approved by the FDA with unknown efficacy and possible adverse effects. Probably the increasing number of studies worldwide examining the potential COVID-19 related therapies will help to identification of effective ARDS treatment. In this review article, we first provide a summary on immunopathology of ARDS next we will give an overview of management of patients with COVID-19 requiring intensive care unit (ICU), while focusing on the current treatment strategies being evaluated in the clinical trials in COVID-19-induced ARDS patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a ARDS | |
| 650 | 4 | |a Acute respiratory distress syndrome | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Pandemics | |
| 650 | 4 | |a SARS-CoV-2 | |
| 700 | 1 | |a Aslan, Cynthia |e verfasserin |4 aut | |
| 700 | 1 | |a Zolbanin, Naime Majidi |e verfasserin |4 aut | |
| 700 | 1 | |a Jafari, Reza |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pneumonia (Nathan Qld.) |d 2012 |g 13(2021), 1 vom: 06. Dez., Seite 14 |w (DE-627)NLM252001591 |x 2200-6133 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2021 |g number:1 |g day:06 |g month:12 |g pages:14 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s41479-021-00092-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2021 |e 1 |b 06 |c 12 |h 14 | ||